Clinical trial · Interventional
Study of XL999 in Patients With Multiple Myeloma
A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT00304590CI-TRIAL-00003175terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was terminated due to cardiac toxicities in the subjects
Summary
Brief summary (as posted)
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| XL999 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Response rate
- timeFrame
- Inclusion of subject until disease progression
- measure
- Safety and tolerability
- timeFrame
- Inclusion until 30 days post last treatment
Secondary outcomes (3)
- measure
- Duration of response
- timeFrame
- Inclusion until disease progression
- measure
- Progression-free survival
- timeFrame
- Inclusion until disease progression
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males and females with a diagnosis of MM based on bone marrow aspirate and biopsy with ≥10% plasma cells (or biopsy of a tissue with monoclonal plasma cells), M protein level in the serum or urine, and evidence of end organ or tissue impairment (hypercalcemia, renal insufficiency, anemia, or lytic bone lesions), as defined by The International Myeloma Working Group Criteria (2003), at initial diagnosis (before initiation of chemotherapy) * Measurable disease defined as serum and/or urine M component by electrophoresis * Refractory to or relapsed after 2 prior treatment regimens (chemotherapy, biologic or hematopoietic stem cell transplantation) * Concurrent therapy with a bisphosphonate is acceptable * ECOG performance status of 0 or 1 * Life expectancy ≥3 months * Adequate liver function * No other malignancies within 5 years * Signed informed consent Exclusion Criteria: * Nonsecretory myeloma, monoclonal gammopathy of uncertain significance (MGUS), or smoldering myeloma * Anticancer therapy including chemotherapeutic, biologic, or investigational agents, including dexamethasone, within 30 days of XL999 treatment * Hematopoietic stem cell transplantation within the previous 6 weeks * Radiation to ≥33% of bone marrow within 30 days of XL999 treatment * Subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to investigational or chemotherapeutic drugs that were administered \>30 prior to study enrollment * Uncontrolled and/or intercurrent illness * Pregnant or breastfeeding females * Known HIV
References
Publications (0)
Data not yet available
No reference posted for this study.